Fentanyl Injectable Syringes Recalled Due to Sterility Assurance Failure
Central Admixture Pharmacy Services is recalling 1,216 fentanyl 2500 mcg/50 mL syringes distributed nationwide due to lack of validation data for sanitization cycles, which cannot assure sterility.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The hazard involves potential contamination due to lack of sterility assurance for an injectable product, which represents a risk-of-harm product where injury has not yet been reported. Per the rubric, when no illnesses are reported and the hazard is theoretical, the maximum score is 3.
Plain-English summary
Central Admixture Pharmacy Services Inc. is recalling fentanyl 2500 mcg/50 mL (50 mcg/mL) syringes distributed nationwide. The affected product is supplied in 50 mL syringes with NDC 71286-2003-3, and 1,216 syringes are included in the recall.
The recall was initiated because the manufacturer lacked adequate validation data for sanitization cycles. Without proper validation, the sterility of the injectable product cannot be assured, which is critical for medications administered intravenously or intramuscularly.
Multiple lot numbers are affected by this recall, with expiration dates ranging from July 2023 through September 2023. Healthcare professionals should refer to the FDA recall notice for specific lot numbers and expiration dates.
The recalled product
- Product
- fentaNYL, 2500 mcg/50 mL, (50 mcg/mL), 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2003-3
- Manufacturer
- Central Admixture Pharmacy Services Inc
- Category
- Drug — Injectable Fentanyl
- Affected units
- 1,216
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (16)
- Lot: 17-270771
- Exp. 7/19/2023
- 17-271134
- Exp. 7/25/2023
- 17-271577
- Exp. 8/1/2023
- 17-271745
- Exp. 8/3/2023
- 17-272026
- Exp. 8/9/2023
- 17-272345
- Exp. 8/15/2023
- 17-272615
- Exp. 8/20/2023
- 17-273668
- Exp. 9/6/2023.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 39 recalled by Central Admixture Pharmacy Services Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 39 products in this recall →Related recalls
Same manufacturer · Central Admixture Pharmacy Services Inc
See all →- ModeratePediatric TPN Bags Recalled for Incorrect Formulation
FDA (Drugs) · 2026-08-12
- SeverePediatric Total Parenteral Nutrition Bag Recalled for Incorrect Formulation
FDA (Drugs) · 2026-07-01
- SevereInjectable Phenylephrine Solution Recalled Due to Particulate Matter Contamination
FDA (Drugs) · 2025-03-19
- HighInjectable Lidocaine Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighMidazolam Injectable Solution Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2023-10-11
Same hazard · lack of sterility
See all →- HighRohto Cooling Eye Drops Max Strength Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15